Catalyst Biosciences, Inc. CBIO · Stock Open Catalyst Biosciences, Inc. in new tab
Catalyst Biosciences, Inc. Analysis (CBIO)
Is Catalyst Biosciences, Inc. a good investment? Catalyst Biosciences, Inc. (CBIO) is currently trading at 14.26 USD. Market analysts have a consensus price target of 30.60 USD. This suggests a potential upside from current levels.
Earnings Schedule: Catalyst Biosciences, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.63.
Investor FAQ
Does Catalyst Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Catalyst Biosciences, Inc.?
Catalyst Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.14.
Company Profile
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
| Year | Total Dividends |
|---|---|
| ▸2023 |
24.24 USD
|
| Jan. 13, 2023 | 0.2400 |
| Jan. 13, 2023 | 24.0000 |
| ▸2022 |
144.43 USD
|
| Sept. 21, 2022 | 1.4300 |
| Sept. 21, 2022 | 143.0000 |
| Split Date | Split Ratio to 1 |
|---|---|
| June 16, 2025 | 1:100 |
Community Discussion